| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Herpesvirus 4, Human | 130 | 2024 | 954 | 10.230 |
Why?
|
| T-Lymphocytes, Cytotoxic | 110 | 2020 | 1020 | 10.150 |
Why?
|
| Immunotherapy, Adoptive | 105 | 2024 | 1841 | 8.530 |
Why?
|
| T-Lymphocytes | 109 | 2024 | 3947 | 7.140 |
Why?
|
| Epstein-Barr Virus Infections | 49 | 2024 | 475 | 6.030 |
Why?
|
| Lymphoma | 29 | 2024 | 1514 | 3.490 |
Why?
|
| Receptors, Antigen, T-Cell | 38 | 2024 | 1136 | 3.360 |
Why?
|
| Viral Matrix Proteins | 24 | 2018 | 182 | 3.100 |
Why?
|
| Lymphoproliferative Disorders | 37 | 2015 | 382 | 2.820 |
Why?
|
| Antigens, Viral | 30 | 2024 | 520 | 2.470 |
Why?
|
| Adoptive Transfer | 32 | 2019 | 436 | 2.460 |
Why?
|
| Killer Cells, Natural | 15 | 2023 | 967 | 2.280 |
Why?
|
| Hodgkin Disease | 31 | 2024 | 1488 | 2.100 |
Why?
|
| Adenoviridae | 33 | 2019 | 1514 | 2.060 |
Why?
|
| Virus Diseases | 12 | 2023 | 392 | 1.830 |
Why?
|
| Genetic Therapy | 16 | 2018 | 1739 | 1.830 |
Why?
|
| Cell- and Tissue-Based Therapy | 14 | 2023 | 382 | 1.810 |
Why?
|
| Immunotherapy | 38 | 2023 | 3546 | 1.760 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 50 | 2023 | 6987 | 1.750 |
Why?
|
| Cytomegalovirus | 23 | 2019 | 493 | 1.690 |
Why?
|
| Lymphocyte Activation | 47 | 2019 | 1728 | 1.620 |
Why?
|
| T-Lymphocyte Subsets | 12 | 2017 | 595 | 1.590 |
Why?
|
| Genetic Vectors | 35 | 2019 | 1887 | 1.590 |
Why?
|
| Dendritic Cells | 28 | 2017 | 1113 | 1.510 |
Why?
|
| Antigens, Neoplasm | 23 | 2021 | 1590 | 1.480 |
Why?
|
| Herpesviridae Infections | 17 | 2013 | 181 | 1.460 |
Why?
|
| Neuroblastoma | 11 | 2019 | 703 | 1.430 |
Why?
|
| Antigens, CD19 | 16 | 2019 | 584 | 1.380 |
Why?
|
| Interleukin-7 | 6 | 2023 | 93 | 1.310 |
Why?
|
| Cell Culture Techniques | 11 | 2016 | 584 | 1.300 |
Why?
|
| CD4-Positive T-Lymphocytes | 21 | 2020 | 1054 | 1.290 |
Why?
|
| Bone Marrow Transplantation | 23 | 2014 | 1772 | 1.270 |
Why?
|
| Epitopes, T-Lymphocyte | 17 | 2020 | 228 | 1.270 |
Why?
|
| Transduction, Genetic | 22 | 2017 | 497 | 1.220 |
Why?
|
| Cytotoxicity, Immunologic | 30 | 2019 | 683 | 1.190 |
Why?
|
| Tumor Virus Infections | 11 | 2012 | 249 | 1.150 |
Why?
|
| Adenoviridae Infections | 8 | 2013 | 114 | 1.140 |
Why?
|
| Recombinant Fusion Proteins | 27 | 2019 | 1668 | 1.110 |
Why?
|
| Burkitt Lymphoma | 17 | 2011 | 350 | 1.080 |
Why?
|
| Lymphoma, B-Cell | 10 | 2022 | 936 | 1.020 |
Why?
|
| Cell Proliferation | 35 | 2019 | 7302 | 1.000 |
Why?
|
| Humans | 294 | 2024 | 272087 | 1.000 |
Why?
|
| Antigen-Presenting Cells | 12 | 2014 | 289 | 0.970 |
Why?
|
| Cytokines | 20 | 2023 | 2841 | 0.890 |
Why?
|
| K562 Cells | 9 | 2019 | 345 | 0.860 |
Why?
|
| Leukocytes, Mononuclear | 14 | 2023 | 718 | 0.840 |
Why?
|
| Tumor Escape | 5 | 2018 | 248 | 0.810 |
Why?
|
| Gene Transfer Techniques | 13 | 2012 | 813 | 0.800 |
Why?
|
| Epstein-Barr Virus Nuclear Antigens | 17 | 2018 | 76 | 0.790 |
Why?
|
| Musculoskeletal Diseases | 1 | 2023 | 96 | 0.790 |
Why?
|
| Graft vs Host Disease | 17 | 2022 | 2804 | 0.770 |
Why?
|
| CD8-Positive T-Lymphocytes | 18 | 2020 | 1659 | 0.770 |
Why?
|
| Neoplasms | 19 | 2022 | 15930 | 0.750 |
Why?
|
| Cancer Vaccines | 7 | 2014 | 754 | 0.740 |
Why?
|
| Interleukin-12 | 6 | 2015 | 267 | 0.740 |
Why?
|
| Caspase 9 | 9 | 2015 | 188 | 0.730 |
Why?
|
| Tumor Microenvironment | 7 | 2023 | 3026 | 0.720 |
Why?
|
| Smallpox | 1 | 2020 | 10 | 0.720 |
Why?
|
| Animals | 69 | 2024 | 62822 | 0.720 |
Why?
|
| Smallpox Vaccine | 1 | 2020 | 42 | 0.700 |
Why?
|
| Immunophenotyping | 26 | 2023 | 1732 | 0.700 |
Why?
|
| HLA Antigens | 11 | 2023 | 588 | 0.700 |
Why?
|
| B-Lymphocytes | 20 | 2013 | 1429 | 0.690 |
Why?
|
| Immunologic Memory | 9 | 2015 | 380 | 0.690 |
Why?
|
| Regenerative Medicine | 2 | 2019 | 40 | 0.680 |
Why?
|
| Cells, Cultured | 34 | 2020 | 5788 | 0.670 |
Why?
|
| Interleukin-15 | 9 | 2017 | 189 | 0.670 |
Why?
|
| Mice | 49 | 2024 | 36053 | 0.670 |
Why?
|
| DNA Transposable Elements | 8 | 2018 | 252 | 0.660 |
Why?
|
| Transplantation, Homologous | 23 | 2022 | 3036 | 0.660 |
Why?
|
| Immune System Diseases | 2 | 2018 | 65 | 0.660 |
Why?
|
| Ki-1 Antigen | 5 | 2024 | 186 | 0.660 |
Why?
|
| Myeloid-Derived Suppressor Cells | 1 | 2019 | 103 | 0.600 |
Why?
|
| Antigen Presentation | 15 | 2024 | 289 | 0.590 |
Why?
|
| DNA Virus Infections | 4 | 2017 | 27 | 0.590 |
Why?
|
| Oncolytic Viruses | 3 | 2020 | 165 | 0.580 |
Why?
|
| T-Cell Antigen Receptor Specificity | 11 | 2017 | 94 | 0.580 |
Why?
|
| Cell Line | 42 | 2017 | 5433 | 0.580 |
Why?
|
| Genes, Transgenic, Suicide | 7 | 2015 | 63 | 0.570 |
Why?
|
| Interferon-gamma | 8 | 2020 | 1180 | 0.570 |
Why?
|
| Flow Cytometry | 21 | 2017 | 3078 | 0.570 |
Why?
|
| Microbiota | 1 | 2023 | 545 | 0.550 |
Why?
|
| Epitopes | 11 | 2020 | 708 | 0.530 |
Why?
|
| Graft Rejection | 2 | 2019 | 865 | 0.530 |
Why?
|
| Interleukin-2 | 8 | 2017 | 891 | 0.520 |
Why?
|
| Receptors, Antigen | 3 | 2014 | 68 | 0.500 |
Why?
|
| Immunocompromised Host | 8 | 2012 | 721 | 0.500 |
Why?
|
| Cell Line, Transformed | 13 | 2014 | 431 | 0.500 |
Why?
|
| Antigens | 6 | 2010 | 283 | 0.490 |
Why?
|
| Oncogene Proteins, Viral | 2 | 2013 | 148 | 0.480 |
Why?
|
| Child, Preschool | 47 | 2024 | 17056 | 0.480 |
Why?
|
| Retroviridae | 12 | 2019 | 376 | 0.480 |
Why?
|
| Immunosuppressive Agents | 9 | 2012 | 1443 | 0.470 |
Why?
|
| Leukocyte Common Antigens | 5 | 2023 | 192 | 0.470 |
Why?
|
| Diphtheria Toxin | 1 | 2014 | 83 | 0.460 |
Why?
|
| Vaccinia virus | 4 | 2020 | 85 | 0.450 |
Why?
|
| Cell Line, Tumor | 28 | 2024 | 14881 | 0.440 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 7 | 2019 | 2903 | 0.440 |
Why?
|
| Genes, Viral | 9 | 2012 | 257 | 0.430 |
Why?
|
| Transplantation Immunology | 4 | 2006 | 107 | 0.430 |
Why?
|
| Mice, SCID | 18 | 2015 | 1851 | 0.430 |
Why?
|
| Factor X | 1 | 2012 | 10 | 0.430 |
Why?
|
| Chemotaxis, Leukocyte | 2 | 2010 | 161 | 0.430 |
Why?
|
| Viral Proteins | 10 | 2018 | 493 | 0.430 |
Why?
|
| Papillomavirus E7 Proteins | 1 | 2013 | 64 | 0.430 |
Why?
|
| Lymphocyte Transfusion | 7 | 2007 | 174 | 0.420 |
Why?
|
| fas Receptor | 4 | 2017 | 197 | 0.420 |
Why?
|
| Child | 56 | 2024 | 30559 | 0.420 |
Why?
|
| Combined Modality Therapy | 9 | 2020 | 9046 | 0.420 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 4 | 2021 | 48 | 0.420 |
Why?
|
| Phosphoproteins | 7 | 2012 | 1230 | 0.410 |
Why?
|
| Virus Replication | 8 | 2020 | 773 | 0.410 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 13 | 2016 | 1534 | 0.410 |
Why?
|
| Immune System | 1 | 2014 | 277 | 0.400 |
Why?
|
| Oncolytic Virotherapy | 5 | 2020 | 235 | 0.400 |
Why?
|
| Adolescent | 47 | 2024 | 32730 | 0.400 |
Why?
|
| Gangliosides | 3 | 2024 | 97 | 0.390 |
Why?
|
| Glioblastoma | 3 | 2017 | 1781 | 0.390 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2017 | 802 | 0.380 |
Why?
|
| CD28 Antigens | 9 | 2017 | 204 | 0.380 |
Why?
|
| Human papillomavirus 16 | 1 | 2013 | 257 | 0.380 |
Why?
|
| Nasopharyngeal Neoplasms | 8 | 2014 | 337 | 0.370 |
Why?
|
| Receptor, ErbB-2 | 6 | 2017 | 2649 | 0.370 |
Why?
|
| Virus Latency | 5 | 2024 | 79 | 0.370 |
Why?
|
| Xenograft Model Antitumor Assays | 11 | 2024 | 3929 | 0.370 |
Why?
|
| Coculture Techniques | 9 | 2019 | 631 | 0.370 |
Why?
|
| Interleukin-1 Receptor-Associated Kinases | 1 | 2010 | 37 | 0.360 |
Why?
|
| Female | 78 | 2024 | 149288 | 0.360 |
Why?
|
| Leukemia, Myeloid, Acute | 8 | 2023 | 7258 | 0.360 |
Why?
|
| Genetic Markers | 10 | 1998 | 1077 | 0.360 |
Why?
|
| Recurrence | 15 | 2022 | 4887 | 0.350 |
Why?
|
| Transgenes | 9 | 2018 | 589 | 0.350 |
Why?
|
| Leukemia, Myeloid | 2 | 2014 | 994 | 0.350 |
Why?
|
| DNA, Viral | 17 | 2011 | 764 | 0.350 |
Why?
|
| Male | 80 | 2024 | 129088 | 0.340 |
Why?
|
| Amino Acid Sequence | 14 | 2020 | 4635 | 0.340 |
Why?
|
| Immunity, Cellular | 10 | 2023 | 442 | 0.330 |
Why?
|
| Stem Cells | 2 | 2015 | 1236 | 0.320 |
Why?
|
| Apoptosis | 11 | 2011 | 7837 | 0.320 |
Why?
|
| CD3 Complex | 6 | 2017 | 321 | 0.310 |
Why?
|
| Immunity, Innate | 1 | 2012 | 690 | 0.310 |
Why?
|
| T-Lymphocytes, Regulatory | 5 | 2012 | 716 | 0.310 |
Why?
|
| Histocompatibility Antigens Class I | 4 | 2019 | 247 | 0.310 |
Why?
|
| Capsid Proteins | 3 | 2007 | 220 | 0.310 |
Why?
|
| Mice, Inbred NOD | 8 | 2017 | 910 | 0.300 |
Why?
|
| Postoperative Complications | 11 | 2012 | 5693 | 0.300 |
Why?
|
| Leukemia | 8 | 2022 | 1721 | 0.300 |
Why?
|
| Cytomegalovirus Infections | 5 | 2019 | 487 | 0.300 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2014 | 506 | 0.300 |
Why?
|
| Cell Survival | 8 | 2017 | 3074 | 0.300 |
Why?
|
| CD27 Ligand | 2 | 2021 | 26 | 0.290 |
Why?
|
| Cross Reactions | 3 | 2004 | 264 | 0.290 |
Why?
|
| Vaccination | 5 | 2023 | 1156 | 0.280 |
Why?
|
| Sirolimus | 1 | 2011 | 833 | 0.280 |
Why?
|
| Blotting, Western | 7 | 2015 | 3646 | 0.270 |
Why?
|
| Tissue Transplantation | 2 | 2005 | 26 | 0.270 |
Why?
|
| Single-Chain Antibodies | 2 | 2021 | 60 | 0.270 |
Why?
|
| Fetal Blood | 5 | 2011 | 502 | 0.270 |
Why?
|
| Fluorescent Dyes | 1 | 2008 | 468 | 0.270 |
Why?
|
| DNA Viruses | 3 | 2017 | 45 | 0.260 |
Why?
|
| Lymphoma, Non-Hodgkin | 6 | 2018 | 1068 | 0.260 |
Why?
|
| Cell Transformation, Viral | 6 | 2012 | 175 | 0.260 |
Why?
|
| Treatment Outcome | 25 | 2021 | 33909 | 0.260 |
Why?
|
| 4-1BB Ligand | 2 | 2017 | 13 | 0.260 |
Why?
|
| Young Adult | 19 | 2024 | 22142 | 0.250 |
Why?
|
| Adult | 45 | 2022 | 81933 | 0.250 |
Why?
|
| Time Factors | 15 | 2018 | 13139 | 0.250 |
Why?
|
| Receptors, OX40 | 2 | 2024 | 51 | 0.250 |
Why?
|
| NF-kappa B | 2 | 2017 | 1569 | 0.240 |
Why?
|
| Transfection | 11 | 2013 | 3166 | 0.240 |
Why?
|
| Repressor Proteins | 1 | 2013 | 1730 | 0.240 |
Why?
|
| Influenza, Human | 1 | 2011 | 763 | 0.240 |
Why?
|
| Lymphocyte Depletion | 5 | 2020 | 311 | 0.240 |
Why?
|
| Virus Activation | 6 | 2018 | 236 | 0.240 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2011 | 1575 | 0.240 |
Why?
|
| HIV-1 | 4 | 2018 | 641 | 0.240 |
Why?
|
| Peptides | 6 | 2024 | 1529 | 0.230 |
Why?
|
| Blood Component Removal | 2 | 2016 | 121 | 0.230 |
Why?
|
| Lymphocyte Count | 3 | 2017 | 485 | 0.220 |
Why?
|
| Cell Separation | 6 | 2012 | 616 | 0.220 |
Why?
|
| Gene Expression | 12 | 2018 | 3690 | 0.220 |
Why?
|
| Brain Neoplasms | 5 | 2017 | 4994 | 0.220 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2010 | 2085 | 0.210 |
Why?
|
| Interleukin-10 | 3 | 1997 | 482 | 0.210 |
Why?
|
| Molecular Sequence Data | 13 | 2005 | 6783 | 0.210 |
Why?
|
| Immunodominant Epitopes | 2 | 2012 | 64 | 0.210 |
Why?
|
| Neoplasm Transplantation | 3 | 2023 | 1566 | 0.210 |
Why?
|
| Tissue Donors | 6 | 2020 | 812 | 0.210 |
Why?
|
| Drug Resistance, Neoplasm | 4 | 2014 | 5421 | 0.200 |
Why?
|
| Neoplasms, Experimental | 3 | 2015 | 790 | 0.200 |
Why?
|
| Lymphoma, T-Cell | 2 | 2018 | 369 | 0.200 |
Why?
|
| Immunoglobulin kappa-Chains | 2 | 2016 | 73 | 0.200 |
Why?
|
| HLA-A Antigens | 5 | 2011 | 105 | 0.200 |
Why?
|
| Hematopoietic Stem Cells | 4 | 2016 | 1373 | 0.200 |
Why?
|
| Receptors, Interleukin-7 | 2 | 2014 | 49 | 0.200 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 9 | 2 | 2024 | 76 | 0.200 |
Why?
|
| Stem Cell Transplantation | 7 | 2020 | 1423 | 0.200 |
Why?
|
| Tumor Cells, Cultured | 9 | 2011 | 5804 | 0.200 |
Why?
|
| Financing, Government | 1 | 2021 | 38 | 0.190 |
Why?
|
| CD4 Antigens | 1 | 2002 | 171 | 0.190 |
Why?
|
| Cell Engineering | 2 | 2018 | 35 | 0.190 |
Why?
|
| Middle Aged | 33 | 2021 | 90460 | 0.190 |
Why?
|
| Lymphoma, Extranodal NK-T-Cell | 1 | 2021 | 35 | 0.190 |
Why?
|
| Neoplasm Proteins | 4 | 2021 | 3363 | 0.190 |
Why?
|
| Viral Structural Proteins | 1 | 2001 | 61 | 0.190 |
Why?
|
| Viral Load | 8 | 2019 | 482 | 0.190 |
Why?
|
| Interleukin-7 Receptor alpha Subunit | 2 | 2024 | 25 | 0.190 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2023 | 508 | 0.180 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 2 | 2019 | 186 | 0.180 |
Why?
|
| Heterografts | 1 | 2023 | 745 | 0.180 |
Why?
|
| Hematologic Neoplasms | 3 | 2022 | 1950 | 0.180 |
Why?
|
| Measles virus | 1 | 2020 | 17 | 0.180 |
Why?
|
| Infant | 19 | 2024 | 13970 | 0.180 |
Why?
|
| Adenoviruses, Human | 4 | 2017 | 191 | 0.180 |
Why?
|
| Cell Transplantation | 3 | 2017 | 89 | 0.180 |
Why?
|
| Receptors, Transforming Growth Factor beta | 3 | 2008 | 229 | 0.180 |
Why?
|
| Phylogeny | 1 | 2023 | 870 | 0.180 |
Why?
|
| Antigens, CD20 | 4 | 2006 | 207 | 0.170 |
Why?
|
| Mutant Chimeric Proteins | 2 | 2017 | 25 | 0.170 |
Why?
|
| Organ Transplantation | 2 | 2001 | 203 | 0.170 |
Why?
|
| HIV Infections | 3 | 2018 | 2158 | 0.170 |
Why?
|
| Virion | 1 | 2020 | 186 | 0.170 |
Why?
|
| Liver Transplantation | 5 | 2011 | 1184 | 0.170 |
Why?
|
| Transplantation, Autologous | 6 | 2018 | 2048 | 0.160 |
Why?
|
| Cell Differentiation | 7 | 2017 | 4195 | 0.160 |
Why?
|
| Antiretroviral Therapy, Highly Active | 2 | 2018 | 309 | 0.160 |
Why?
|
| Viruses | 2 | 2014 | 156 | 0.160 |
Why?
|
| beta 2-Microglobulin | 1 | 2019 | 189 | 0.160 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2024 | 550 | 0.160 |
Why?
|
| Signal Transduction | 6 | 2018 | 12223 | 0.160 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily K | 1 | 2019 | 58 | 0.160 |
Why?
|
| Leukemia, B-Cell | 3 | 2010 | 114 | 0.160 |
Why?
|
| HLA-A2 Antigen | 5 | 2011 | 172 | 0.150 |
Why?
|
| Base Sequence | 8 | 2015 | 5502 | 0.150 |
Why?
|
| Adenovirus Infections, Human | 2 | 2009 | 55 | 0.150 |
Why?
|
| Bacteria | 1 | 2023 | 652 | 0.150 |
Why?
|
| Plasmids | 7 | 2015 | 953 | 0.150 |
Why?
|
| Protein Domains | 1 | 2019 | 324 | 0.150 |
Why?
|
| HEK293 Cells | 6 | 2021 | 1470 | 0.150 |
Why?
|
| Chemokines | 1 | 2019 | 296 | 0.150 |
Why?
|
| Leukemia-Lymphoma, Adult T-Cell | 1 | 2017 | 72 | 0.150 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 3 | 2017 | 388 | 0.140 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 6 | 2010 | 3651 | 0.140 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 3 | 2016 | 2474 | 0.140 |
Why?
|
| Osteosarcoma | 3 | 2015 | 948 | 0.140 |
Why?
|
| Interleukin-1 | 1 | 2018 | 477 | 0.140 |
Why?
|
| Erythropoietin | 1 | 2018 | 219 | 0.140 |
Why?
|
| Remission Induction | 5 | 2016 | 3645 | 0.140 |
Why?
|
| Lectins, C-Type | 1 | 2017 | 163 | 0.140 |
Why?
|
| Cytotoxicity Tests, Immunologic | 4 | 2007 | 85 | 0.140 |
Why?
|
| Vaccines, Attenuated | 1 | 2017 | 190 | 0.140 |
Why?
|
| Lymphocyte Subsets | 1 | 2017 | 138 | 0.140 |
Why?
|
| Receptors, Cytokine | 1 | 2017 | 183 | 0.140 |
Why?
|
| Lymphocytes | 5 | 2023 | 1280 | 0.140 |
Why?
|
| CD8 Antigens | 2 | 2015 | 173 | 0.140 |
Why?
|
| Multiple Myeloma | 3 | 2020 | 2287 | 0.140 |
Why?
|
| Herpesvirus 6, Human | 2 | 2017 | 81 | 0.140 |
Why?
|
| Feeder Cells | 1 | 2016 | 11 | 0.130 |
Why?
|
| Ligands | 1 | 2019 | 1057 | 0.130 |
Why?
|
| Gene Expression Regulation, Leukemic | 2 | 2017 | 582 | 0.130 |
Why?
|
| Mucin-1 | 2 | 2013 | 164 | 0.130 |
Why?
|
| Osteolysis | 1 | 1996 | 99 | 0.130 |
Why?
|
| Phenotype | 10 | 2018 | 6517 | 0.130 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 4 | 2014 | 2634 | 0.130 |
Why?
|
| Receptors, CCR7 | 1 | 2015 | 38 | 0.130 |
Why?
|
| Transforming Growth Factor beta | 5 | 2010 | 1133 | 0.130 |
Why?
|
| Macrophages | 2 | 2018 | 1378 | 0.120 |
Why?
|
| Promoter Regions, Genetic | 4 | 1992 | 3262 | 0.120 |
Why?
|
| Spleen | 2 | 2015 | 731 | 0.120 |
Why?
|
| HIV Antigens | 1 | 2014 | 26 | 0.120 |
Why?
|
| Cell Movement | 4 | 2012 | 2504 | 0.120 |
Why?
|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2015 | 67 | 0.120 |
Why?
|
| Polymerase Chain Reaction | 8 | 2015 | 3512 | 0.120 |
Why?
|
| Chromosomes, Artificial, Bacterial | 1 | 2015 | 130 | 0.120 |
Why?
|
| Blood Donors | 3 | 2011 | 173 | 0.120 |
Why?
|
| Lentivirus | 4 | 2017 | 166 | 0.120 |
Why?
|
| Tacrolimus | 2 | 2009 | 351 | 0.120 |
Why?
|
| Interleukin-4 Receptor alpha Subunit | 1 | 2014 | 15 | 0.120 |
Why?
|
| Peptide Fragments | 5 | 2011 | 1327 | 0.120 |
Why?
|
| Immunologic Factors | 1 | 2018 | 669 | 0.120 |
Why?
|
| Graft vs Leukemia Effect | 1 | 2014 | 107 | 0.120 |
Why?
|
| Gene Editing | 1 | 2016 | 231 | 0.120 |
Why?
|
| Gamma Rays | 1 | 2014 | 241 | 0.110 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2016 | 255 | 0.110 |
Why?
|
| Aspergillosis, Allergic Bronchopulmonary | 1 | 2013 | 33 | 0.110 |
Why?
|
| Adult Stem Cells | 1 | 2014 | 69 | 0.110 |
Why?
|
| Tacrolimus Binding Proteins | 2 | 2011 | 83 | 0.110 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 4 | 2010 | 879 | 0.110 |
Why?
|
| Research Support as Topic | 1 | 2014 | 120 | 0.110 |
Why?
|
| RNA, Small Interfering | 3 | 2010 | 2219 | 0.110 |
Why?
|
| Antineoplastic Agents | 8 | 2022 | 14653 | 0.110 |
Why?
|
| CRISPR-Cas Systems | 1 | 2016 | 353 | 0.110 |
Why?
|
| Granulomatous Disease, Chronic | 1 | 2013 | 73 | 0.110 |
Why?
|
| Flutamide | 1 | 2013 | 51 | 0.110 |
Why?
|
| Th1 Cells | 2 | 2013 | 260 | 0.110 |
Why?
|
| Cell Division | 4 | 2003 | 2711 | 0.110 |
Why?
|
| RNA, Messenger | 6 | 2010 | 6489 | 0.110 |
Why?
|
| Cell Death | 3 | 2017 | 689 | 0.100 |
Why?
|
| Program Development | 1 | 2014 | 264 | 0.100 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2014 | 194 | 0.100 |
Why?
|
| Roseolovirus Infections | 1 | 2012 | 39 | 0.100 |
Why?
|
| Bone Neoplasms | 3 | 2015 | 2669 | 0.100 |
Why?
|
| Salvage Therapy | 1 | 2021 | 2119 | 0.100 |
Why?
|
| Neoplastic Stem Cells | 4 | 2011 | 1469 | 0.100 |
Why?
|
| Caspases | 2 | 2005 | 687 | 0.100 |
Why?
|
| Green Fluorescent Proteins | 4 | 2015 | 703 | 0.100 |
Why?
|
| Antibodies, Monoclonal | 9 | 2008 | 4496 | 0.100 |
Why?
|
| Receptors, Chemokine | 1 | 2012 | 114 | 0.100 |
Why?
|
| Models, Biological | 4 | 2012 | 3223 | 0.100 |
Why?
|
| Cryopreservation | 1 | 2012 | 171 | 0.100 |
Why?
|
| Aged | 14 | 2021 | 73517 | 0.090 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 1992 | 197 | 0.090 |
Why?
|
| Chills | 1 | 2010 | 12 | 0.090 |
Why?
|
| Home Infusion Therapy | 1 | 2010 | 10 | 0.090 |
Why?
|
| Cerebral Revascularization | 1 | 1991 | 25 | 0.090 |
Why?
|
| Neomycin | 3 | 2000 | 47 | 0.090 |
Why?
|
| Neoplasm Recurrence, Local | 6 | 2018 | 10365 | 0.090 |
Why?
|
| Monocytes | 3 | 2012 | 789 | 0.090 |
Why?
|
| Receptors, CCR2 | 1 | 2010 | 45 | 0.090 |
Why?
|
| Risk Factors | 9 | 2015 | 18051 | 0.090 |
Why?
|
| Moyamoya Disease | 1 | 1991 | 42 | 0.090 |
Why?
|
| Clinical Trials as Topic | 4 | 2012 | 3856 | 0.090 |
Why?
|
| Postoperative Nausea and Vomiting | 1 | 2010 | 43 | 0.090 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2017 | 1091 | 0.090 |
Why?
|
| B7-1 Antigen | 2 | 2007 | 85 | 0.090 |
Why?
|
| Enzyme Induction | 2 | 2014 | 262 | 0.090 |
Why?
|
| Carcinoma | 3 | 2014 | 2623 | 0.090 |
Why?
|
| Follow-Up Studies | 7 | 2022 | 15279 | 0.090 |
Why?
|
| Receptors, Virus | 2 | 2010 | 153 | 0.090 |
Why?
|
| Bone Marrow Purging | 5 | 1996 | 88 | 0.090 |
Why?
|
| Tacrolimus Binding Protein 1A | 1 | 2009 | 21 | 0.090 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2015 | 6270 | 0.090 |
Why?
|
| Antibody Specificity | 2 | 2001 | 340 | 0.090 |
Why?
|
| BK Virus | 2 | 2017 | 126 | 0.080 |
Why?
|
| Mice, Inbred BALB C | 3 | 2010 | 2470 | 0.080 |
Why?
|
| Organic Chemicals | 3 | 2015 | 103 | 0.080 |
Why?
|
| Wnt Proteins | 1 | 2011 | 392 | 0.080 |
Why?
|
| Drugs, Investigational | 1 | 2010 | 129 | 0.080 |
Why?
|
| Disease Models, Animal | 6 | 2024 | 7476 | 0.080 |
Why?
|
| Receptors, CCR4 | 1 | 2009 | 35 | 0.080 |
Why?
|
| Recoverin | 1 | 2008 | 19 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2017 | 5107 | 0.080 |
Why?
|
| Antigens, Surface | 3 | 1986 | 311 | 0.080 |
Why?
|
| Peptide Library | 2 | 2011 | 165 | 0.080 |
Why?
|
| Melanoma | 3 | 2015 | 5592 | 0.080 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2014 | 1015 | 0.080 |
Why?
|
| Feasibility Studies | 6 | 2016 | 2355 | 0.080 |
Why?
|
| Biological Specimen Banks | 1 | 2008 | 74 | 0.080 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 1 | 2010 | 208 | 0.080 |
Why?
|
| Spectrometry, Fluorescence | 1 | 2008 | 207 | 0.080 |
Why?
|
| Azacitidine | 2 | 2013 | 1219 | 0.080 |
Why?
|
| Sequence Analysis, DNA | 2 | 2015 | 2576 | 0.080 |
Why?
|
| Mice, Inbred C57BL | 5 | 2013 | 7237 | 0.080 |
Why?
|
| Membrane Glycoproteins | 3 | 2013 | 1105 | 0.080 |
Why?
|
| Genes | 1 | 1989 | 613 | 0.080 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2011 | 1351 | 0.080 |
Why?
|
| Brain Ischemia | 1 | 1991 | 316 | 0.080 |
Why?
|
| Organisms, Genetically Modified | 1 | 2007 | 14 | 0.080 |
Why?
|
| Immune Tolerance | 3 | 2007 | 431 | 0.080 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2012 | 1132 | 0.080 |
Why?
|
| Antibodies, Viral | 4 | 2023 | 1296 | 0.070 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2017 | 1335 | 0.070 |
Why?
|
| Spectroscopy, Near-Infrared | 1 | 2008 | 173 | 0.070 |
Why?
|
| B7-2 Antigen | 1 | 2007 | 53 | 0.070 |
Why?
|
| Viral Vaccines | 1 | 2010 | 358 | 0.070 |
Why?
|
| Herpesvirus 3, Human | 1 | 2007 | 44 | 0.070 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2013 | 848 | 0.070 |
Why?
|
| Histocompatibility Antigens Class II | 3 | 2003 | 191 | 0.070 |
Why?
|
| MART-1 Antigen | 1 | 2007 | 113 | 0.070 |
Why?
|
| Fever | 1 | 2010 | 516 | 0.070 |
Why?
|
| Optics and Photonics | 1 | 2008 | 164 | 0.070 |
Why?
|
| Calcium Phosphates | 1 | 2007 | 15 | 0.070 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2008 | 207 | 0.070 |
Why?
|
| Cyclophosphamide | 3 | 2020 | 3231 | 0.070 |
Why?
|
| Interleukins | 1 | 2009 | 342 | 0.070 |
Why?
|
| Conserved Sequence | 2 | 2007 | 499 | 0.070 |
Why?
|
| Gene Knockdown Techniques | 1 | 2009 | 1085 | 0.070 |
Why?
|
| Transplantation, Heterologous | 3 | 2014 | 1086 | 0.070 |
Why?
|
| Disease-Free Survival | 4 | 2013 | 10259 | 0.070 |
Why?
|
| Genome, Human | 1 | 2015 | 1885 | 0.070 |
Why?
|
| In Vitro Techniques | 3 | 2010 | 1742 | 0.070 |
Why?
|
| Recombinant Proteins | 4 | 2003 | 3072 | 0.070 |
Why?
|
| HLA-DR Antigens | 2 | 2003 | 184 | 0.070 |
Why?
|
| Reproducibility of Results | 2 | 2010 | 6210 | 0.070 |
Why?
|
| Integrins | 2 | 2023 | 278 | 0.070 |
Why?
|
| Prostatic Neoplasms | 2 | 2013 | 5996 | 0.070 |
Why?
|
| Haplotypes | 3 | 2015 | 909 | 0.070 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2015 | 2357 | 0.060 |
Why?
|
| Myeloid Cells | 2 | 2017 | 277 | 0.060 |
Why?
|
| Sequence Homology, Amino Acid | 2 | 2001 | 1093 | 0.060 |
Why?
|
| Alleles | 4 | 2004 | 2599 | 0.060 |
Why?
|
| Chromium | 1 | 2005 | 12 | 0.060 |
Why?
|
| Down-Regulation | 2 | 2015 | 2106 | 0.060 |
Why?
|
| Gene Deletion | 3 | 2016 | 1487 | 0.060 |
Why?
|
| Receptors, Interleukin-2 | 2 | 2003 | 195 | 0.060 |
Why?
|
| Nerve Tissue Proteins | 1 | 2013 | 1599 | 0.060 |
Why?
|
| Cation Transport Proteins | 1 | 2006 | 172 | 0.060 |
Why?
|
| Immunologic Surveillance | 1 | 1985 | 61 | 0.060 |
Why?
|
| Gammaretrovirus | 2 | 2017 | 6 | 0.060 |
Why?
|
| Genetic Engineering | 3 | 2014 | 298 | 0.060 |
Why?
|
| COS Cells | 1 | 2005 | 423 | 0.060 |
Why?
|
| Fas Ligand Protein | 1 | 2005 | 154 | 0.060 |
Why?
|
| Tumor Burden | 1 | 2010 | 2035 | 0.060 |
Why?
|
| Jurkat Cells | 1 | 2005 | 320 | 0.060 |
Why?
|
| Ovalbumin | 2 | 2018 | 391 | 0.060 |
Why?
|
| Gene Expression Regulation | 4 | 1989 | 4200 | 0.060 |
Why?
|
| Epitope Mapping | 1 | 2004 | 110 | 0.060 |
Why?
|
| Immunohistochemistry | 3 | 2015 | 7828 | 0.060 |
Why?
|
| Papillomavirus Infections | 1 | 2013 | 1014 | 0.060 |
Why?
|
| Sarcoma | 1 | 2015 | 1842 | 0.060 |
Why?
|
| Cell Communication | 1 | 2007 | 518 | 0.060 |
Why?
|
| HLA-B Antigens | 1 | 2024 | 59 | 0.060 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2017 | 9101 | 0.060 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2013 | 1159 | 0.060 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2012 | 1905 | 0.060 |
Why?
|
| Luminescent Proteins | 2 | 2001 | 307 | 0.060 |
Why?
|
| Caspase 3 | 1 | 2005 | 481 | 0.060 |
Why?
|
| Transposases | 2 | 2015 | 69 | 0.060 |
Why?
|
| Infectious Mononucleosis | 2 | 1997 | 38 | 0.060 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2014 | 2174 | 0.060 |
Why?
|
| Sensitivity and Specificity | 2 | 2005 | 5196 | 0.050 |
Why?
|
| Immunity | 2 | 2004 | 356 | 0.050 |
Why?
|
| JC Virus | 1 | 2003 | 48 | 0.050 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2005 | 320 | 0.050 |
Why?
|
| Virus Shedding | 1 | 2003 | 92 | 0.050 |
Why?
|
| Aspergillus fumigatus | 2 | 2014 | 138 | 0.050 |
Why?
|
| HLA-DP Antigens | 1 | 2002 | 20 | 0.050 |
Why?
|
| Vidarabine | 2 | 2020 | 1383 | 0.050 |
Why?
|
| Survival Rate | 3 | 2013 | 12534 | 0.050 |
Why?
|
| Texas | 1 | 2013 | 6440 | 0.050 |
Why?
|
| Transplants | 1 | 2003 | 51 | 0.050 |
Why?
|
| United States | 6 | 2021 | 16066 | 0.050 |
Why?
|
| Thymidine Kinase | 1 | 2003 | 224 | 0.050 |
Why?
|
| Infusions, Intravenous | 2 | 2010 | 1442 | 0.050 |
Why?
|
| Transplantation Conditioning | 3 | 2017 | 2359 | 0.050 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2013 | 1913 | 0.050 |
Why?
|
| Carrier State | 1 | 2002 | 86 | 0.050 |
Why?
|
| Medulloblastoma | 1 | 2007 | 586 | 0.050 |
Why?
|
| THP-1 Cells | 1 | 2021 | 55 | 0.050 |
Why?
|
| Mice, Transgenic | 4 | 2014 | 4371 | 0.050 |
Why?
|
| HLA-A11 Antigen | 1 | 2001 | 3 | 0.050 |
Why?
|
| Culture Media, Conditioned | 1 | 2002 | 257 | 0.050 |
Why?
|
| Disease Progression | 3 | 2017 | 6911 | 0.050 |
Why?
|
| Government Regulation | 1 | 2021 | 59 | 0.050 |
Why?
|
| Trans-Activators | 3 | 2018 | 1660 | 0.050 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2015 | 1212 | 0.050 |
Why?
|
| Prognosis | 7 | 2021 | 22555 | 0.050 |
Why?
|
| Hydroxamic Acids | 2 | 2015 | 455 | 0.050 |
Why?
|
| Molecular Targeted Therapy | 3 | 2017 | 2400 | 0.050 |
Why?
|
| Safety | 3 | 2006 | 465 | 0.050 |
Why?
|
| CD40 Ligand | 1 | 2001 | 131 | 0.050 |
Why?
|
| Antiviral Agents | 2 | 2005 | 1255 | 0.050 |
Why?
|
| Rituximab | 4 | 2010 | 1588 | 0.050 |
Why?
|
| Sarcoma, Ewing | 2 | 2015 | 426 | 0.050 |
Why?
|
| Academies and Institutes | 1 | 2021 | 96 | 0.050 |
Why?
|
| Mice, Knockout | 4 | 2013 | 5841 | 0.050 |
Why?
|
| Cyclosporine | 1 | 2001 | 296 | 0.040 |
Why?
|
| DiGeorge Syndrome | 1 | 2001 | 81 | 0.040 |
Why?
|
| Telomerase | 1 | 2003 | 543 | 0.040 |
Why?
|
| Receptors, IgG | 1 | 2000 | 116 | 0.040 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2008 | 850 | 0.040 |
Why?
|
| Bendamustine Hydrochloride | 1 | 2020 | 122 | 0.040 |
Why?
|
| Biopsy | 4 | 2006 | 3544 | 0.040 |
Why?
|
| Kidney Transplantation | 1 | 2006 | 792 | 0.040 |
Why?
|
| Receptors, Tumor Necrosis Factor | 2 | 2014 | 214 | 0.040 |
Why?
|
| Histocompatibility Testing | 3 | 2009 | 484 | 0.040 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2000 | 220 | 0.040 |
Why?
|
| Chronic Disease | 4 | 2011 | 1855 | 0.040 |
Why?
|
| Thymus Gland | 1 | 2001 | 312 | 0.040 |
Why?
|
| Symporters | 1 | 2020 | 105 | 0.040 |
Why?
|
| HeLa Cells | 2 | 2015 | 1718 | 0.040 |
Why?
|
| Neoplasm Grading | 1 | 2024 | 1827 | 0.040 |
Why?
|
| Breast Neoplasms | 1 | 2024 | 16244 | 0.040 |
Why?
|
| Liver Neoplasms | 2 | 2014 | 4811 | 0.040 |
Why?
|
| Pancreatic Neoplasms | 1 | 2017 | 5248 | 0.040 |
Why?
|
| Cellular Senescence | 1 | 2001 | 392 | 0.040 |
Why?
|
| Sequence Alignment | 1 | 2001 | 883 | 0.040 |
Why?
|
| Blotting, Southern | 2 | 2000 | 455 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2020 | 16612 | 0.040 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2014 | 4963 | 0.040 |
Why?
|
| Fatal Outcome | 1 | 2001 | 835 | 0.040 |
Why?
|
| DNA-Binding Proteins | 5 | 2003 | 5067 | 0.040 |
Why?
|
| Immunoenzyme Techniques | 2 | 2011 | 1209 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2022 | 529 | 0.040 |
Why?
|
| Bone Marrow Cells | 2 | 2007 | 983 | 0.040 |
Why?
|
| Forkhead Transcription Factors | 2 | 2012 | 772 | 0.040 |
Why?
|
| Fibroblasts | 1 | 2004 | 1670 | 0.040 |
Why?
|
| Sequence Deletion | 1 | 2001 | 915 | 0.040 |
Why?
|
| Graft vs Tumor Effect | 1 | 1998 | 143 | 0.040 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2001 | 609 | 0.040 |
Why?
|
| Immunization | 1 | 1999 | 402 | 0.040 |
Why?
|
| Enhancer Elements, Genetic | 2 | 1990 | 504 | 0.040 |
Why?
|
| Immunoglobulins | 3 | 2007 | 289 | 0.030 |
Why?
|
| Up-Regulation | 2 | 2014 | 2457 | 0.030 |
Why?
|
| Head Injuries, Closed | 1 | 1996 | 47 | 0.030 |
Why?
|
| Genes, Dominant | 2 | 2008 | 360 | 0.030 |
Why?
|
| Lymph Nodes | 1 | 2007 | 3080 | 0.030 |
Why?
|
| Vaccines, Synthetic | 2 | 2010 | 371 | 0.030 |
Why?
|
| Interleukin-4 | 1 | 2017 | 291 | 0.030 |
Why?
|
| Chromosome Deletion | 3 | 1990 | 1056 | 0.030 |
Why?
|
| Gene Knockout Techniques | 1 | 2016 | 272 | 0.030 |
Why?
|
| Protein Structure, Tertiary | 2 | 2011 | 1501 | 0.030 |
Why?
|
| Cell Cycle | 1 | 2001 | 2150 | 0.030 |
Why?
|
| Mutation | 5 | 2024 | 15944 | 0.030 |
Why?
|
| Autoimmune Diseases | 1 | 1999 | 433 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 1996 | 172 | 0.030 |
Why?
|
| Antigenic Variation | 1 | 1995 | 40 | 0.030 |
Why?
|
| Batch Cell Culture Techniques | 1 | 2014 | 7 | 0.030 |
Why?
|
| Neuroectodermal Tumors | 1 | 2015 | 33 | 0.030 |
Why?
|
| Immunoglobulin G | 2 | 2014 | 1140 | 0.030 |
Why?
|
| Age Factors | 3 | 2011 | 5526 | 0.030 |
Why?
|
| Forms and Records Control | 1 | 2014 | 26 | 0.030 |
Why?
|
| Inflammation Mediators | 1 | 2017 | 408 | 0.030 |
Why?
|
| Culture Media, Serum-Free | 1 | 2014 | 81 | 0.030 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2014 | 43 | 0.030 |
Why?
|
| Hematopoiesis | 1 | 2018 | 608 | 0.030 |
Why?
|
| 5' Untranslated Regions | 1 | 2015 | 99 | 0.030 |
Why?
|
| Injections, Intralesional | 1 | 2014 | 166 | 0.030 |
Why?
|
| Nuclear Proteins | 1 | 2006 | 3472 | 0.030 |
Why?
|
| Positron-Emission Tomography | 2 | 2015 | 2198 | 0.030 |
Why?
|
| Etanercept | 1 | 2014 | 69 | 0.030 |
Why?
|
| DNA Probes | 1 | 1994 | 248 | 0.030 |
Why?
|
| Antibodies | 2 | 2012 | 819 | 0.030 |
Why?
|
| NADPH Oxidase 2 | 1 | 2013 | 44 | 0.030 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2014 | 211 | 0.030 |
Why?
|
| Immunoconjugates | 1 | 2017 | 314 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2000 | 1143 | 0.030 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2015 | 591 | 0.030 |
Why?
|
| Artifacts | 1 | 1996 | 536 | 0.030 |
Why?
|
| Clone Cells | 2 | 2002 | 589 | 0.030 |
Why?
|
| Protein Engineering | 1 | 2013 | 99 | 0.030 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 1994 | 143 | 0.030 |
Why?
|
| CD2 Antigens | 1 | 2012 | 30 | 0.030 |
Why?
|
| Interleukin Receptor Common gamma Subunit | 1 | 2012 | 46 | 0.030 |
Why?
|
| NADPH Oxidases | 1 | 2013 | 148 | 0.030 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2013 | 172 | 0.030 |
Why?
|
| Glioma | 1 | 2024 | 1988 | 0.030 |
Why?
|
| Species Specificity | 1 | 2014 | 810 | 0.030 |
Why?
|
| Dogs | 1 | 2014 | 1169 | 0.030 |
Why?
|
| Restriction Mapping | 2 | 1990 | 336 | 0.030 |
Why?
|
| Membrane Proteins | 1 | 2003 | 2975 | 0.030 |
Why?
|
| Kinetics | 2 | 2007 | 2242 | 0.030 |
Why?
|
| Neoplasm Metastasis | 2 | 2015 | 5330 | 0.030 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2018 | 879 | 0.030 |
Why?
|
| Drug Resistance | 2 | 2009 | 615 | 0.030 |
Why?
|
| Aspergillosis | 1 | 2014 | 249 | 0.030 |
Why?
|
| Data Collection | 1 | 2014 | 624 | 0.020 |
Why?
|
| Chemokine CXCL10 | 1 | 2012 | 106 | 0.020 |
Why?
|
| Toxicity Tests | 1 | 2012 | 51 | 0.020 |
Why?
|
| Chimera | 1 | 2012 | 152 | 0.020 |
Why?
|
| Radiography | 1 | 1996 | 1994 | 0.020 |
Why?
|
| Anti-HIV Agents | 1 | 2015 | 353 | 0.020 |
Why?
|
| Antigens, Tumor-Associated, Carbohydrate | 1 | 2011 | 120 | 0.020 |
Why?
|
| Maximum Tolerated Dose | 1 | 2015 | 1323 | 0.020 |
Why?
|
| Molecular Weight | 2 | 1989 | 727 | 0.020 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2013 | 426 | 0.020 |
Why?
|
| Neoplasm, Residual | 2 | 2011 | 1741 | 0.020 |
Why?
|
| Prednisone | 1 | 2014 | 1036 | 0.020 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2011 | 156 | 0.020 |
Why?
|
| Flagellin | 1 | 2010 | 23 | 0.020 |
Why?
|
| Collateral Circulation | 1 | 1991 | 53 | 0.020 |
Why?
|
| Chloramphenicol O-Acetyltransferase | 1 | 1990 | 139 | 0.020 |
Why?
|
| Ischemic Attack, Transient | 1 | 1991 | 66 | 0.020 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2014 | 636 | 0.020 |
Why?
|
| Japan | 1 | 2011 | 237 | 0.020 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2014 | 460 | 0.020 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2014 | 319 | 0.020 |
Why?
|
| Immediate-Early Proteins | 1 | 2011 | 109 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2015 | 7792 | 0.020 |
Why?
|
| Bone Marrow Neoplasms | 1 | 2011 | 128 | 0.020 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 1990 | 252 | 0.020 |
Why?
|
| Transplantation | 1 | 2010 | 56 | 0.020 |
Why?
|
| Cerebral Angiography | 1 | 1991 | 148 | 0.020 |
Why?
|
| Immunization, Secondary | 1 | 2010 | 116 | 0.020 |
Why?
|
| Coxsackie and Adenovirus Receptor-Like Membrane Protein | 1 | 2010 | 40 | 0.020 |
Why?
|
| Human T-lymphotropic virus 1 | 1 | 1990 | 103 | 0.020 |
Why?
|
| Predictive Value of Tests | 2 | 2011 | 5001 | 0.020 |
Why?
|
| CD5 Antigens | 1 | 1990 | 130 | 0.020 |
Why?
|
| Androgen Antagonists | 1 | 2013 | 433 | 0.020 |
Why?
|
| T Cell Transcription Factor 1 | 1 | 2009 | 9 | 0.020 |
Why?
|
| Transcription Initiation Site | 1 | 2009 | 47 | 0.020 |
Why?
|
| Internet | 1 | 2014 | 702 | 0.020 |
Why?
|
| Early Diagnosis | 1 | 2011 | 316 | 0.020 |
Why?
|
| Biomarkers | 3 | 2010 | 5115 | 0.020 |
Why?
|
| In Situ Hybridization | 1 | 2012 | 1061 | 0.020 |
Why?
|
| Chemokine CCL2 | 1 | 2010 | 203 | 0.020 |
Why?
|
| Mutagenicity Tests | 1 | 2009 | 70 | 0.020 |
Why?
|
| Blood Cells | 1 | 2010 | 130 | 0.020 |
Why?
|
| Lymphoid Enhancer-Binding Factor 1 | 1 | 2009 | 35 | 0.020 |
Why?
|
| Antigens, Differentiation | 1 | 1990 | 253 | 0.020 |
Why?
|
| Chemokine CCL17 | 1 | 2009 | 14 | 0.020 |
Why?
|
| Chemokine CCL22 | 1 | 2009 | 14 | 0.020 |
Why?
|
| Ribosomal Protein S6 Kinases | 1 | 2009 | 123 | 0.020 |
Why?
|
| Receptors, Lymphocyte Homing | 1 | 2009 | 30 | 0.020 |
Why?
|
| DNA, Recombinant | 1 | 1989 | 161 | 0.020 |
Why?
|
| Defective Viruses | 1 | 1989 | 38 | 0.020 |
Why?
|
| Reed-Sternberg Cells | 1 | 2009 | 46 | 0.020 |
Why?
|
| Cloning, Molecular | 1 | 1992 | 1458 | 0.020 |
Why?
|
| Carotid Artery Diseases | 1 | 1991 | 177 | 0.020 |
Why?
|
| Electric Stimulation | 1 | 1990 | 492 | 0.020 |
Why?
|
| Antigens, CD | 2 | 2007 | 1436 | 0.020 |
Why?
|
| Deoxyribonuclease EcoRI | 1 | 1988 | 10 | 0.020 |
Why?
|
| Contracts | 1 | 2008 | 9 | 0.020 |
Why?
|
| United States Food and Drug Administration | 1 | 2010 | 330 | 0.020 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2013 | 621 | 0.020 |
Why?
|
| DNA Repair | 1 | 2016 | 1912 | 0.020 |
Why?
|
| Diagnosis, Differential | 2 | 1996 | 4900 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2012 | 968 | 0.020 |
Why?
|
| Melanoma, Experimental | 1 | 2010 | 385 | 0.020 |
Why?
|
| Congresses as Topic | 1 | 2010 | 296 | 0.020 |
Why?
|
| RNA, Viral | 1 | 2011 | 729 | 0.020 |
Why?
|
| Th2 Cells | 1 | 2009 | 253 | 0.020 |
Why?
|
| Simian virus 40 | 1 | 1988 | 248 | 0.020 |
Why?
|
| Immunoglobulin Isotypes | 1 | 2007 | 34 | 0.020 |
Why?
|
| Pyrroles | 1 | 2011 | 592 | 0.020 |
Why?
|
| Aged, 80 and over | 2 | 2017 | 31066 | 0.020 |
Why?
|
| Histocompatibility Antigens | 1 | 2007 | 79 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2014 | 2290 | 0.020 |
Why?
|
| Prospective Studies | 3 | 2007 | 13410 | 0.020 |
Why?
|
| CpG Islands | 1 | 2009 | 662 | 0.020 |
Why?
|
| Transcription, Genetic | 3 | 1990 | 3417 | 0.020 |
Why?
|
| Lipopolysaccharide Receptors | 1 | 2007 | 90 | 0.020 |
Why?
|
| Education, Medical, Continuing | 1 | 2008 | 234 | 0.020 |
Why?
|
| Genetic Variation | 1 | 1995 | 2157 | 0.020 |
Why?
|
| Neprilysin | 1 | 1986 | 64 | 0.020 |
Why?
|
| DNA Damage | 1 | 2015 | 1989 | 0.020 |
Why?
|
| Severe Combined Immunodeficiency | 1 | 2007 | 112 | 0.020 |
Why?
|
| Immunoglobulin lambda-Chains | 1 | 2006 | 45 | 0.020 |
Why?
|
| Substrate Specificity | 1 | 2007 | 582 | 0.020 |
Why?
|
| Stromal Cells | 1 | 2010 | 835 | 0.020 |
Why?
|
| Reoperation | 1 | 1991 | 1391 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2012 | 2365 | 0.020 |
Why?
|
| Algorithms | 2 | 2008 | 3925 | 0.020 |
Why?
|
| Mothers | 1 | 2009 | 418 | 0.020 |
Why?
|
| Lymphocyte Function-Associated Antigen-1 | 1 | 1985 | 73 | 0.020 |
Why?
|
| RNA, Neoplasm | 1 | 2008 | 810 | 0.020 |
Why?
|
| Antibody Formation | 1 | 2006 | 386 | 0.020 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 1989 | 473 | 0.020 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2009 | 815 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 1998 | 3176 | 0.020 |
Why?
|
| Mucopolysaccharidosis I | 1 | 2004 | 7 | 0.020 |
Why?
|
| 3' Untranslated Regions | 1 | 2006 | 339 | 0.020 |
Why?
|
| Dimerization | 1 | 2005 | 318 | 0.010 |
Why?
|
| Deoxycytidine | 1 | 2010 | 1378 | 0.010 |
Why?
|
| Protein Kinases | 1 | 1989 | 919 | 0.010 |
Why?
|
| Adenosine Triphosphate | 1 | 2006 | 593 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2017 | 9500 | 0.010 |
Why?
|
| Antigen-Antibody Reactions | 1 | 2004 | 89 | 0.010 |
Why?
|
| Sialic Acids | 1 | 1984 | 24 | 0.010 |
Why?
|
| Epigenesis, Genetic | 1 | 2011 | 1439 | 0.010 |
Why?
|
| Neuraminidase | 1 | 1984 | 46 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2009 | 2256 | 0.010 |
Why?
|
| Postoperative Period | 1 | 1986 | 671 | 0.010 |
Why?
|
| Virulence | 1 | 2005 | 352 | 0.010 |
Why?
|
| Myelodysplastic Syndromes | 2 | 2014 | 3148 | 0.010 |
Why?
|
| Serrate-Jagged Proteins | 1 | 2003 | 85 | 0.010 |
Why?
|
| Cold Temperature | 1 | 1984 | 127 | 0.010 |
Why?
|
| Insecta | 1 | 2003 | 88 | 0.010 |
Why?
|
| beta-Galactosidase | 1 | 1984 | 278 | 0.010 |
Why?
|
| Hydroxyurea | 1 | 2004 | 224 | 0.010 |
Why?
|
| Retrospective Studies | 2 | 2022 | 39831 | 0.010 |
Why?
|
| Jagged-1 Protein | 1 | 2003 | 103 | 0.010 |
Why?
|
| ABO Blood-Group System | 1 | 1984 | 125 | 0.010 |
Why?
|
| Feces | 1 | 2007 | 866 | 0.010 |
Why?
|
| HLA-DP beta-Chains | 1 | 2002 | 16 | 0.010 |
Why?
|
| Urine | 1 | 2003 | 142 | 0.010 |
Why?
|
| Immunotoxins | 1 | 2003 | 120 | 0.010 |
Why?
|
| Gene Targeting | 1 | 2004 | 321 | 0.010 |
Why?
|
| Erythrocytes | 1 | 1984 | 340 | 0.010 |
Why?
|
| Immunoglobulin Fragments | 1 | 2002 | 27 | 0.010 |
Why?
|
| Smad2 Protein | 1 | 2002 | 92 | 0.010 |
Why?
|
| Saliva | 1 | 2003 | 238 | 0.010 |
Why?
|
| Receptors, Fc | 1 | 2002 | 72 | 0.010 |
Why?
|
| Lymphocyte Culture Test, Mixed | 1 | 2001 | 97 | 0.010 |
Why?
|
| Homeostasis | 1 | 2007 | 959 | 0.010 |
Why?
|
| Cell Membrane | 1 | 1985 | 900 | 0.010 |
Why?
|
| Models, Immunological | 1 | 2001 | 79 | 0.010 |
Why?
|
| Seasons | 1 | 2003 | 338 | 0.010 |
Why?
|
| Hepatitis B e Antigens | 1 | 2000 | 13 | 0.010 |
Why?
|
| Calcium-Binding Proteins | 1 | 2003 | 557 | 0.010 |
Why?
|
| Nucleocapsid | 1 | 2000 | 13 | 0.010 |
Why?
|
| Hepatitis B Core Antigens | 1 | 2000 | 28 | 0.010 |
Why?
|
| Genome-Wide Association Study | 1 | 2009 | 2333 | 0.010 |
Why?
|
| Antibodies, Neoplasm | 1 | 2002 | 275 | 0.010 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 2000 | 52 | 0.010 |
Why?
|
| Injections, Intraperitoneal | 1 | 2000 | 210 | 0.010 |
Why?
|
| Polymorphism, Genetic | 1 | 2006 | 1559 | 0.010 |
Why?
|
| Receptors, Notch | 1 | 2003 | 377 | 0.010 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2003 | 673 | 0.010 |
Why?
|
| Protein Binding | 1 | 2007 | 3528 | 0.010 |
Why?
|
| Rats | 1 | 2009 | 6640 | 0.010 |
Why?
|
| Alu Elements | 1 | 2000 | 90 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 1985 | 1740 | 0.010 |
Why?
|
| Proto-Oncogene Proteins | 1 | 1989 | 2624 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2014 | 13993 | 0.010 |
Why?
|
| Sequence Homology, Nucleic Acid | 2 | 1990 | 422 | 0.010 |
Why?
|
| Pyrimidines | 1 | 2011 | 3664 | 0.010 |
Why?
|
| Hepatitis B virus | 1 | 2000 | 225 | 0.010 |
Why?
|
| CD40 Antigens | 1 | 1999 | 107 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2011 | 6885 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2015 | 7958 | 0.010 |
Why?
|
| Adjuvants, Immunologic | 1 | 2002 | 692 | 0.010 |
Why?
|
| Drug Resistance, Microbial | 1 | 1998 | 243 | 0.010 |
Why?
|
| Precipitin Tests | 1 | 1997 | 360 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2003 | 2058 | 0.010 |
Why?
|
| CHO Cells | 1 | 1997 | 323 | 0.010 |
Why?
|
| Neutralization Tests | 1 | 1997 | 281 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 1998 | 596 | 0.010 |
Why?
|
| Cricetinae | 1 | 1997 | 793 | 0.010 |
Why?
|
| Nuclear Family | 1 | 1996 | 68 | 0.010 |
Why?
|
| Histocompatibility | 1 | 1996 | 182 | 0.010 |
Why?
|
| Infant, Newborn | 2 | 2004 | 8612 | 0.010 |
Why?
|
| Transcription Factors | 1 | 1989 | 5506 | 0.010 |
Why?
|
| Kanamycin Kinase | 1 | 1994 | 22 | 0.010 |
Why?
|
| Moloney murine leukemia virus | 1 | 1994 | 36 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2006 | 5756 | 0.010 |
Why?
|
| Monitoring, Physiologic | 1 | 1995 | 537 | 0.010 |
Why?
|
| Mycoses | 1 | 1996 | 396 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 1997 | 1615 | 0.010 |
Why?
|
| Bacterial Infections | 1 | 1996 | 507 | 0.010 |
Why?
|
| Clinical Protocols | 1 | 1994 | 485 | 0.010 |
Why?
|
| Brain | 1 | 2004 | 4257 | 0.010 |
Why?
|
| Informed Consent | 1 | 1994 | 415 | 0.010 |
Why?
|
| Nucleotide Mapping | 1 | 1990 | 29 | 0.010 |
Why?
|
| Oligonucleotide Probes | 1 | 1990 | 158 | 0.010 |
Why?
|
| Butyrates | 1 | 1989 | 58 | 0.010 |
Why?
|
| Gene Products, tat | 1 | 1989 | 65 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-fos | 1 | 1989 | 134 | 0.000 |
Why?
|
| Proto-Oncogene Proteins c-jun | 1 | 1989 | 177 | 0.000 |
Why?
|
| Fungal Proteins | 1 | 1989 | 272 | 0.000 |
Why?
|
| Receptors, Complement 3d | 1 | 1986 | 9 | 0.000 |
Why?
|
| Protein Biosynthesis | 1 | 1990 | 1035 | 0.000 |
Why?
|
| New Guinea | 1 | 1985 | 3 | 0.000 |
Why?
|
| Africa | 1 | 1985 | 148 | 0.000 |
Why?
|
| Binding Sites | 1 | 1989 | 2298 | 0.000 |
Why?
|
| Skin Neoplasms | 1 | 2000 | 4890 | 0.000 |
Why?
|
| Incidence | 1 | 1994 | 5864 | 0.000 |
Why?
|
| Karyotyping | 1 | 1985 | 1064 | 0.000 |
Why?
|